Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8 PF-07321332 Boceprevir Intermediate
Mea Kūʻai Kūʻai PF-07321332 Paxlovid E pili ana i waena me ke kūlana kiʻekiʻe.
L-tert-Leucine (H-Tle-OH) CAS 20859-02-3
Caronic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
Inoa Kimia | Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate |
Nā huaʻōlelo like | Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate;(αS,3S)-α-[(tert-Butyloxycarbonyl)aMino]-2-oxo-3-pyrrolidinepropanoic acid Methyl Ester;(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate |
Helu CAS | 328086-60-8 |
Helu CAT | RF-PI317 |
Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
ʻĀpana Molekala | C13H22N2O5 |
Kaumaha Molecular | 286.33 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
ʻIkepili A | IR: E like me ka mea kuhikuhi |
ʻIkepili B | Manawa Hoʻopaʻa: E like me ka mea kuhikuhi |
Nalo ma ka maloo | ≤1.0% |
Koena ma ka Ignition | ≤0.20% |
Hoʻokahi haumia | ≤0.50% |
Huina paumaele | ≤2.0% |
Nā Metala Kaumaha (Pb) | ≤20ppm |
Maemae | ≥98.0% |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | Kūwaena o PF-07321332 Paxlovid (CAS 2628280-40-8) a me Boceprevir (CAS 394730-60-0) |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl] propanoate (CAS 328086-60-8) ka mea waena o PF-07321332 Paxlovid (CAS 2628280-40 -8) a me Boceprevir (CAS 394730-60-0).ʻO PF-07321332, ka mea koʻikoʻi o Paxlovid (PF-07321332 a me Ritonavir) he moho antiviral waha COVID-19 i hoʻokolokolo ʻia, he 3C-like protease (3CLPRO) i hiki i ka waha me nā hopena antiviral ikaika e kūʻē i ka maʻi SARS-CoV-2. a me COVID-19.Ma ka lā 6 o Nowemapa 2021, hoʻolaha ʻo Pfizer ua hōʻemi nui ʻo Paxlovid i ka haukapila a me ka make, e pili ana i kahi loiloi interim o ka Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study. o nā poʻe maʻi makua ʻole i hoʻokipa ʻia me COVID-19, ka poʻe i pilikia nui i ka holomua ʻana i ka maʻi koʻikoʻi.ʻO Boceprevir (EBP-520) he mea hoʻopaʻa protease HCV (Ki=14 nM) no ka mālama ʻana i ka maʻi maʻi hepatitis C.ʻO Boceprevir me ka interferon pegylated a me ka ribavirin (PegIFN/RBV) i hiki ai ke hoʻomaikaʻi i nā helu pane virological mau o nā maʻi me ka genotype 1 HCV.Hoʻopili ʻo Boceprevir me ka immunosuppressive therapy (IT) ma ke kāohi ʻana i ka enzyme cytochrome P450 3A.